Warner Bros. Discovery (NASDAQ: WBD) announced a significant delay for its upcoming 'Gremlins' sequel, pushing the release date back by 321 days to October 6, 2028. The move, revealed alongside a brief teaser, removes a major franchise title from the studio's 2027 slate and comes as the company's stock trades just 0.8% below the cash offer from Paramount Global.
On September 23, 2026, WBD shares closed at $30.76, down 0.2% from the previous session. That leaves a spread of only $0.24 (0.78%) to Paramount's $31 per share base payment. Trading volume was heavy at 110.24 million shares, more than four times the three-month average, yet the film delay did not widen the deal spread, indicating that investors remain focused on the acquisition rather than studio operations.
Weak Studio Fundamentals
The delay lands against a backdrop of sharply weaker studio performance. In the second quarter of 2026, Warner Bros. Discovery's Studios segment reported revenue of $2.328 billion, down 39% from $3.801 billion a year earlier. Content revenue fell 41% to $2.125 billion, while adjusted EBITDA plummeted 89% to just $96 million, compared to $863 million in the prior-year period. The adjusted EBITDA margin contracted to 4.1% from 22.7%.
The company has stated it manages its business "as a portfolio of titles with a long-term view," but the latest quarter underscores the pressure on its film and television operations. Despite the weak results, WBD maintains a long-term target of more than $3 billion in annual Studios adjusted EBITDA, supported by a library that has generated roughly $5 billion in yearly revenue.
Paramount Acquisition Overhang
For shareholders, the near-term payoff is tied to the pending acquisition by Paramount Global, which agreed to pay $31 per share in cash. After September 30, 2026, the consideration will increase by $0.00277778 per day until closing, a ticking fee designed to compensate investors for delays.
A significant legal hurdle was cleared on Monday when a settlement with 12 states removed a major obstacle to the deal, although judicial approval is still pending. Morgan Stanley analyst Sean Diffley called the settlement a "clear positive outcome" and raised his price target to $31, maintaining an Equal Weight rating.
Analyst Sentiment and Risks
Current analyst recommendations cluster tightly around the cash consideration. Barclays initiated coverage with an Equal Weight rating and a $29 target, while Bernstein holds with a $28 target. Argus Research remains bullish with a Buy and a $31 target. The narrow range reflects the view that the acquisition price caps upside, but also limits downside unless the deal fails.
If the transaction were to collapse, WBD would face renewed scrutiny over its debt load, declining linear-TV revenue, and film profitability. The 'Gremlins' delay could be seen as prudent if it improves the film's quality, but it also removes a potential box-office boost from 2027. The new teaser only provides a release date and theatrical commitment, with no details on budget or production start.
The next key date is September 30, when the ticking consideration begins to accrue. Until then, investors will watch for further updates on the Paramount deal and any additional studio announcements.
